PIP: To determine the effect of a long-acting injectable progestogen-estrogen contraceptive (Deladroxate) on blood coagulation and fibrinolysis, 67 multiparous women receiving the contraceptive for 12 to 14 cycles aged 18-40 years were followed-up monthly for 1 year. The prothrombin consumption index, prothrombin percentage, whole blood clotting time, plasma fibrinogen, clot retraction, bleeding time, and fibrinolytic activity of all patients were all within normal limits both 6 and 12 months after beginning of treatment. Research on the relationship of contraceptive use and occurrence of thrombophlebitis is contradictory and no valid test for measuring blood coagulability exists that is satisfactory for these investigations. This study concludes nevertheless that no aberrations in blood coagulation occurred from this progestogen-estrogen treatment.